Constrictive Pericarditis: Hemodynamic Diagnosis, Imaging Criteria, and Pericardiectomy Strategy

Constrictive Pericarditis: Hemodynamic Diagnosis, Imaging Criteria, and Pericardiectomy Strategy

Bedside recognition of Kussmaul sign and pericardial knock, multimodality imaging for pericardial thickening and septal bounce, and operative timing for radical pericardiectomy.

CardiologyPericardial DiseaseAuthor: gomdoriUpdated: 2026-06-21

Executive Summary

Constrictive pericarditis is a progressive disorder in which a fibrotic, calcified, or inflamed pericardium encases the heart and impairs diastolic filling. Etiologies vary by region: in high-income settings the dominant causes are post–cardiac surgery, post–chest radiation, and idiopathic/viral disease, whereas tuberculosis still drives most cases in endemic regions and accounts for roughly 70–80% globally. The hallmark hemodynamic signature is dissociation between intrathoracic and intracardiac pressures plus exaggerated ventricular interdependence, producing Kussmaul sign on jugular venous examination, a pericardial knock at the lower left sternal border, and refractory peripheral edema with hepatic congestion that often masquerades as cirrhosis or chronic right heart failure. Echocardiography demonstrates respiratory variation in mitral inflow E-wave (>25%), septal bounce, expiratory hepatic vein diastolic flow reversal, and annulus reversus (medial e′ ≥ lateral e′), while CT and cardiac MRI confirm pericardial thickening >4 mm, calcification, and tethering. Cardiac catheterization shows equalization of end-diastolic pressures within 5 mm Hg, a "square-root" or dip-and-plateau ventricular waveform, and ventricular interdependence with respiration. Hemodynamically stable patients with subacute inflammatory or transient constriction warrant a 3–6 month anti-inflammatory trial of colchicine 0.5 mg PO BID plus ibuprofen 600–800 mg PO TID (full dose for an initial 1–2 weeks and until symptoms resolve and CRP normalizes, then tapered) ± prednisone 0.25–0.5 mg/kg/day taper (prednisone only after infection, particularly bacterial or tuberculous, has been excluded), while chronic fibrocalcific constriction requires radical pericardiectomy with operative mortality of 5–10% in experienced centers. This guideline integrates etiology, multimodality diagnosis, differentiation from restrictive cardiomyopathy, and a stepwise medical-to-surgical pathway with referral thresholds.

70–80%
TB Etiology Globally
>4 mm
CT/MRI Pericardium
>25%
Mitral E Variation
5–10%
Pericardiectomy Mortality

S1 · Etiology, Pathophysiology, and Epidemiology

Constrictive pericarditis arises whenever the parietal pericardium becomes thickened, fibrotic, or calcified to the point that diastolic filling of the cardiac chambers is restricted by an external rigid shell. The pathologic substrate may be acquired over months to decades following an inciting episode of pericardial inflammation, hemorrhage, or infection, and the latency between insult and clinical constriction commonly spans 5–25 years for radiation- or tuberculosis-related cases. Although global epidemiology remains shaped by tuberculosis, which still accounts for 70–80% of constrictive pericarditis worldwide and nearly all cases in sub-Saharan Africa and parts of South Asia, the etiologic profile in high-income centers has shifted: large North American and European pericardiectopublished series consistently show idiopathic or viral disease in 30–45% of cases, post–cardiac surgery in 20–30%, post–chest or mediastinal radiation in 10–15%, autoimmune connective tissue disease in 5–10%, and miscellaneous causes (uremia, drugs, neoplasm, post-MI Dressler syndrome, IgG4-related disease) accounting for the remainder.

Etiologic categories and inciting events

CategoryMechanism / typical courseLatency
TuberculousCaseating granulomatous pericarditis → fibrosis ± dense calcification; HIV co-infection accelerates progression1–5 yr from active TB
Post–cardiac surgeryCABG, valve, congenital repair; postpericardiotomy syndrome with hemorrhagic effusion progressing to fibrosis3 mo – 5 yr post-op
Post-radiationMediastinal RT for Hodgkin lymphoma, breast, lung, esophageal cancer; dose >40 Gy substantially elevates risk; coexisting myocardial fibrosis worsens outcomes5–25 yr post-RT
Idiopathic / viralCoxsackie, echovirus, parvovirus B19, EBV, CMV, adenovirus, SARS-CoV-2; acute pericarditis evolves to constriction in <1% of casesMonths – years
Autoimmune / CTDRheumatoid arthritis, SLE, scleroderma, mixed connective tissue disease, IgG4-RD, sarcoidosisVariable
NeoplasticDirect invasion (lung, breast), metastatic implants (lymphoma, melanoma, mesothelioma), or paraneoplastic effusionMonths
Uremic / dialysisChronic uremic pericarditis with organizing exudate; less common with modern dialysisMonths – years
Drug-inducedProcainamide, hydralazine, isoniazid, phenytoin, minoxidil, methysergide; rare cause of progressionMonths

Pathophysiology of pericardial constraint

The normal pericardium is a thin (1–2 mm) fibroelastic sac that exerts negligible influence on cardiac filling under physiologic conditions. When chronic inflammation, hemorrhage, or radiation injury produces dense fibrosis with or without calcification, the pericardial space loses compliance and the heart is forced to fill within a rigid, fixed-volume container. Three hemodynamic consequences define the syndrome:

Dissociation of intrathoracic and intracardiac pressures. A normal pericardium transmits respiratory pressure swings to all four cardiac chambers and the pulmonary veins simultaneously. A rigid pericardium prevents this transmission, so during inspiration the pulmonary vein pressure falls (because it lies inside the thorax but outside the pericardium) while the left atrial and left ventricular pressures do not, abolishing the gradient that normally drives left-sided filling. This is the mechanism behind expiratory accentuation of left-sided filling and respiratory variation in mitral inflow.

Equalization of end-diastolic pressures. Because the four chambers share a common rigid envelope and reach the constraint point simultaneously, end-diastolic pressures equalize within 5 mm Hg in all chambers — RA, RV, LV end-diastolic, and pulmonary capillary wedge pressures all converge to a common value, typically 18–28 mm Hg. This equalization is preserved across volume loading (saline challenge), distinguishing constriction from many other causes of elevated filling pressures.

Exaggerated ventricular interdependence. With the total cardiac volume fixed by the constraining pericardium, any increase in right ventricular filling must be matched by a reciprocal decrease in left ventricular filling and vice versa. During inspiration, augmented RV filling pushes the interventricular septum leftward (septal bounce on echo and the discordant LV/RV systolic pressure variation on simultaneous left and right cath tracings).

Diastolic dip-and-plateau ("square root sign"). Early diastolic filling is rapid and unimpeded because the pericardial constraint is not yet engaged, producing a steep "y descent" on the venous pressure tracing and a deep dip on the ventricular pressure tracing. As soon as the constraint is reached (within the first third of diastole), filling abruptly stops and pressure plateaus, generating the characteristic dip-and-plateau or "square root" waveform.

Constrictive Pericarditis Pathophysiology Flowchart showing inciting injury leading to pericardial fibrosis, then to hemodynamic consequences and clinical manifestations. Inciting Pericardial Injury TB · Surgery · Radiation · Viral · CTD Pericardial Fibrosis ± Calcification Rigid envelope · loss of compliance Pressure Dissociation Intrathoracic ≠ intracardiac → Mitral E variation >25% Pressure Equalization RA = RV = LV = PCWP within ≤5 mm Hg Ventricular Interdependence Fixed total cardiac volume → septal bounce Clinical Constriction Syndrome Kussmaul sign · pericardial knock · ascites · hepatic congestion · refractory edema · low CO
Figure 1. From inciting pericardial injury to the clinical constriction syndrome via three hemodynamic consequences.

Epidemiology and prognosis

Population-based data are limited because constrictive pericarditis is uncommon and frequently underdiagnosed. The annual incidence of constriction following acute idiopathic or viral pericarditis is approximately 0.5–1 per 1,000 patient-years (less than 1% lifetime risk), rising to 2–5% after pericarditis associated with bacterial or autoimmune etiologies and 30–50% after tuberculous pericarditis without adequate antitubercular therapy. Among cardiac surgery patients, the incidence ranges 0.1–0.3% overall, with higher rates following postoperative pericardial effusion, valve repair, and complex congenital procedures. Untreated chronic constriction carries a 5-year mortality approaching 50% from progressive right heart failure and cardiac cachexia. Pericardiectomy in experienced centers achieves 5-year survival of 60–80% overall but only 25–50% in radiation-induced cases due to coexisting myocardial fibrosis and restrictive disease.

S2 · Clinical Presentation and Bedside Examination

Constrictive pericarditis is frequently misdiagnosed for months or years as cirrhosis, idiopathic ascites, nephrotic syndrome, or right heart failure of unknown etiology, because the dominant clinical picture is one of systemic venous congestion with relatively preserved left ventricular function and clear lung fields. The diagnosis hinges on careful bedside assessment of the jugular venous waveform, an unhurried search for the pericardial knock, and recognition of the disproportionate hepatic congestion and ascites relative to peripheral edema.

Symptoms

  • Progressive exertional dyspnea and fatigue — the most common presenting complaint, reflecting low cardiac output and inability to augment stroke volume on exertion. Dyspnea is typically not orthopneic, distinguishing it from left heart failure.
  • Abdominal distension and early satiety — caused by ascites and hepatic congestion; patients often present first to a gastroenterologist or hepatologist.
  • Lower extremity edema — typically bilateral, pitting, and refractory to escalating diuretics.
  • Cachexia and weight loss — late, ominous feature reflecting protein-losing enteropathy from chronic mesenteric venous congestion and elevated TNF-α; suggests advanced disease.
  • Atrial arrhythmias — atrial fibrillation in 20–40% of patients due to chronic atrial dilation and stretch.
  • Palpitations, presyncope, or syncope — uncommon; suggest critical low output or arrhythmia.

Physical examination

SignDescriptionSensitivity / specificity
Elevated JVPMarkedly elevated, often to the angle of the jaw with the patient sitting upright; prominent x and y descents (M or W pattern); JVP >15 cm H2O in nearly all symptomatic patientsSens 90% / Spec 60%
Kussmaul signParadoxical rise (or failure to fall) in JVP during inspiration; reflects inability of the right heart to accommodate increased venous returnSens 50–60% / Spec 90%
Pericardial knockEarly diastolic high-frequency sound at the lower left sternal border 60–120 ms after S2, louder than S3; coincides with abrupt cessation of ventricular fillingSens 30–60% / Spec 95%
Hepatomegaly with pulsatile liverTender, often markedly enlarged liver (Glisson capsule stretch); pulsatility may be palpable; transmitted v waveSens 70% / Spec 75%
Ascites disproportionate to edemaAscites often dominates over peripheral edema; mimics hepatic cirrhosis; serum-ascites albumin gradient typically >1.1 g/dL (transudate)Sens 65% / Spec 80%
Pulsus paradoxusInspiratory drop in systolic BP >10 mm Hg; less prominent than in cardiac tamponade; present in 20–30% onlySens 25% / Spec 80%
Quiet precordium / muffled heart soundsCalcified or thickened pericardium dampens heart sounds; apex impulse often unimpressiveSens 60% / Spec 60%
Cachexia and muscle wastingLate stigmata of cardiac cachexia and protein-losing enteropathySens 40% / Spec 80%

Beck triad does NOT apply to constriction

The classic Beck triad of cardiac tamponade (hypotension, muffled heart sounds, distended neck veins) is sometimes confused with the presentation of constriction, but the two physiologies differ fundamentally. In tamponade the entire diastolic period is impeded and the y descent is blunted or absent; in constriction early diastolic filling is rapid and the y descent is exaggerated. Pulsus paradoxus is a hallmark of tamponade but is mild or absent in pure constriction; conversely, Kussmaul sign and pericardial knock are characteristic of constriction but absent in tamponade.

Laboratory features

  • Brain natriuretic peptide (BNP / NT-proBNP) — disproportionately low for the degree of congestion (BNP typically <200 pg/mL or NT-proBNP <1,000 pg/mL); a key feature distinguishing constriction from restrictive cardiomyopathy, in which BNP is markedly elevated (>1,000 pg/mL or NT-proBNP >5,000 pg/mL).
  • Hepatic congestion panel — mildly elevated AST/ALT, conjugated hyperbilirubinemia, prolonged INR, and hypoalbuminemia from protein-losing enteropathy.
  • Renal function — pre-renal azotemia from low cardiac output.
  • Inflammatory markers — CRP and ESR may be elevated in transient/inflammatory constriction; normal in chronic fibrocalcific disease.
  • Tuberculosis evaluation — IGRA, PPD, sputum AFB, pericardial fluid ADA >40 U/L if effusion present; in endemic settings or HIV-positive patients, empiric anti-TB therapy may precede confirmatory diagnosis.

Pearl · BNP discrepancy is a high-yield clue

In a patient with marked systemic congestion, ascites, hepatic enlargement, and JVP to the jaw, a BNP under 200 pg/mL should be a red flag for constriction rather than heart failure with preserved ejection fraction or restrictive cardiomyopathy. The pericardium prevents myocardial stretch, so natriuretic peptide release is blunted despite high venous pressures.

Pitfall · Diagnosing "cryptogenic cirrhosis" without examining the JVP

Patients are commonly worked up for unexplained ascites, undergo paracentesis, transient elastography, and even liver biopsy before a cardiologist measures the JVP. Any patient with new ascites and normal liver imaging deserves a careful jugular venous examination at the bedside; finding JVP to the angle of the jaw with prominent y descent should redirect the workup to the pericardium.

S3 · Multimodality Imaging and Hemodynamic Diagnosis

No single test confirms constrictive pericarditis with certainty; the diagnosis emerges from converging evidence across echocardiography, computed tomography, cardiac magnetic resonance imaging, and (in selected cases) invasive hemodynamic catheterization. Echocardiography is the indispensable first imaging study because it directly visualizes ventricular interdependence in real time; CT and MRI characterize pericardial morphology and identify calcification or thickening that an echo cannot reliably assess; and invasive catheterization remains the reference standard when noninvasive findings are equivocal or when distinguishing constriction from restrictive cardiomyopathy.

Echocardiographic criteria (Mayo Clinic 2014 — high specificity)

The Mayo Clinic criteria require demonstration of at least one major and supportive minor features. Diagnostic accuracy approaches 90% sensitivity and 91% specificity when all major features are present.

FeatureThresholdMechanism
1. Respiratory variation in mitral inflow E≥25% increase from inspiration to expirationPressure dissociation between thorax and pericardial space; expiration drives left-sided filling
2. Medial mitral annular e′≥9 cm/s (preserved or augmented)Annulus reversus — pericardial tethering enhances longitudinal motion at the medial annulus while restricting lateral motion
3. Hepatic vein expiratory diastolic flow reversal ratio≥0.79Expiratory rise in RV pressure transmitted to RA and hepatic veins, reversing diastolic flow
Annulus reversusMedial e′ ≥ lateral e′Highly specific; lateral annulus tethered by adherent pericardium, medial annulus spared
Septal bounceAbnormal early diastolic septal motion (rapid leftward then rightward shift)Visual signature of ventricular interdependence in real-time M-mode and 2D imaging
Inferior vena cava plethoraIVC >21 mm with <50% inspiratory collapseReflects elevated right atrial pressure
Strain imagingReduced longitudinal strain at lateral LV wall, preserved at septumPericardial tethering of free wall but not septum

Computed tomography

  • Pericardial thickness >4 mm on ECG-gated cardiac CT — defining structural finding (normal pericardium ≤2 mm). Note: 18–20% of surgically confirmed constriction cases have a pericardium ≤2 mm thick (so-called "constriction without thickening"), particularly in radiation-induced and post-surgical cases.
  • Pericardial calcification — present in 25–35% of cases overall, in up to 50% of TB-related cases, and is highly suggestive of chronic constriction; CT is far superior to chest radiography or MRI for calcium detection.
  • Tubular ventricles, dilated atria, hepatic vein dilation, IVC dilation, pleural effusions, ascites — all support constrictive physiology.
  • Surgical planning — preoperative CT defines the extent of calcification, identifies coronary artery course, and assesses sternal anatomy for re-do thoracotomy.

Cardiac magnetic resonance imaging

  • Pericardial thickening — same threshold (>4 mm); cine sequences depict pericardial morphology in detail.
  • Late gadolinium enhancement (LGE) of pericardium — indicates active pericardial inflammation and identifies patients most likely to respond to anti-inflammatory therapy and have transient or reversible constriction. Strong LGE intensity correlates with C-reactive protein and clinical inflammation markers.
  • Real-time cine MRI — demonstrates septal bounce and respiratory variation analogous to echocardiography but with superior spatial resolution.
  • Tagged MRI — shows pericardial-myocardial tethering with absent slippage between visceral and parietal pericardium during cardiac contraction.

Invasive hemodynamic catheterization

Right heart catheterization with simultaneous left and right ventricular pressure tracings remains the diagnostic gold standard when noninvasive imaging is inconclusive. Required findings:

Hemodynamic findingThreshold / pattern
Equalization of end-diastolic pressuresRA = RV-EDP = LV-EDP = PCWP within 5 mm Hg
Dip-and-plateau / square root signRV and LV diastolic tracings show steep early dip followed by plateau in mid-to-late diastole
RVSP / pulmonary artery systolic pressureUsually <55 mm Hg (helps distinguish from restrictive cardiomyopathy with PASP often >55)
RVEDP / RVSP ratio>1/3 (typical of constriction)
Ventricular interdependence (Hatle's index)Systolic area index = ratio of RV to LV pressure-time area during inspiration vs expiration; >1.1 strongly supports constriction (sens 97% / spec 100%)
Discordance of RV and LV systolic pressures with respirationRV systolic pressure rises during inspiration while LV systolic pressure falls (and reverse during expiration) — reflects fixed total cardiac volume

Diagnosis and management

Constrictive pericarditis: from suspicion to surgery

  1. 1. Suspect it clinically

    • Very high JVP, prominent y descent, Kussmaul sign
    • Pericardial knock; ascites out of proportion to edema
    • BNP disproportionately low; often mistaken for cirrhosis
  2. 2. Echo first, then CT and MRI

    • Echo: septal bounce, respirophasic mitral E, medial e′ ≥ lateral e′
    • CT/MRI: pericardium >4 mm; a normal one does not rule it out
  3. 3. Catheterize if still unclear

    • End-diastolic pressures equal within 5 mm Hg; dip-and-plateau
    • On inspiration, RV systolic pressure rises as LV systolic falls
  4. 4. Hemodynamically stable with active inflammation: anti‑inflammatory trial first

    • Raised CRP or pericardial LGE; recent onset, little calcification
    • Colchicine + NSAID
    • No response after 3–6 months: refer for surgery
  5. 5. No inflammation or failed trial: pericardiectomy

    • Experienced team; complete resection, usually via sternotomy
    • Refer before cachexia, liver dysfunction or renal failure

    Caution: radiation-induced disease, reduced EF, advanced renal disease

  6. 6. After pericardiectomy

    • Low cardiac output may occur in the first 24–48 h: inotropes, judicious volume
    • Persistent ascites, low output or liver dysfunction at 6 months: MRI and repeat hemodynamics

Diurese cautiously before surgery: cardiac output depends on high filling pressures

TB: antituberculous therapy; pericardiectomy if not improving after 4–8 weeks

Step 4 or step 5, depending on active pericardial inflammation. Sources: This article; ASE pericardial imaging, 2013; ESC myocarditis and pericarditis guidelines, 2025

S4 · Differentiating Constriction from Restrictive Cardiomyopathy

The single most important diagnostic question in any patient with right-sided heart failure of unclear etiology is whether the pathology lies outside the heart (constrictive pericarditis, surgically curable) or within the myocardium (restrictive cardiomyopathy, often progressive and incurable apart from transplantation). The two share the clinical phenotype of severe biventricular diastolic dysfunction, elevated filling pressures, and preserved ventricular cavity dimensions, but they diverge sharply on tissue Doppler, BNP, respiratory variation, and pericardial imaging. This differentiation drives the entire management pathway.

Comparative table

FeatureConstrictive PericarditisRestrictive Cardiomyopathy
Underlying pathologyRigid pericardium (extracardiac)Stiff myocardium (amyloid, sarcoid, hemochromatosis, eosinophilic, idiopathic)
BNP / NT-proBNPDisproportionately low (BNP <200, NT-proBNP <1,000)Markedly elevated (often BNP >500, NT-proBNP >5,000)
Pericardium on CT/MRIThickened (>4 mm) ± calcified in 60–80%Normal (≤2 mm) and not calcified
Mitral E respiratory variation≥25% (positive)<10% (negative)
Tissue Doppler medial e′Preserved (≥9 cm/s) — annulus reversusReduced (<7 cm/s)
Hepatic vein flowExpiratory diastolic reversalInspiratory diastolic reversal
Pulmonary artery systolic pressureUsually <55 mm HgOften >55 mm Hg
Septal bouncePresentAbsent
Hatle's ventricular interdependence index>1.1 (positive)<1.1 (negative)
Endomyocardial biopsyNormal myocardiumDiagnostic for amyloid, sarcoid, eosinophilic, etc.
TreatmentPericardiectomy (potentially curative)Disease-specific (anti-amyloid, immunosuppression) ± transplantation

Annulus reversus (constriction)

Medial mitral annular e′ velocity is preserved or augmented (≥9 cm/s) and equals or exceeds the lateral e′. The pericardial tethering immobilizes the lateral free wall but spares the septal/medial annulus, paradoxically enhancing longitudinal motion there. This is the most specific echocardiographic finding for constriction (specificity >95%). The related term annulus paradoxus also describes constriction, not restrictive cardiomyopathy: in most patients with constriction, the usually positive relation between the E/e′ ratio and left atrial pressure is reversed, because medial e′ increases progressively as the constriction becomes more severe (ASE 2013).

Reduced annular e′ (RCM)

Both annular e′ velocities are reduced (<7 cm/s), and the lateral e′ exceeds the medial — the normal physiologic relationship is preserved but values are uniformly depressed by intrinsic myocardial stiffening. Tissue Doppler is reduced because the entire myocardium is diseased.

When to proceed to endomyocardial biopsy

Endomyocardial biopsy is the definitive test to identify infiltrative restrictive cardiomyopathies (amyloid, sarcoid, eosinophilic, hemochromatosis). Indications include:

  • Echocardiographic features atypical for constriction (no septal bounce, normal hepatic vein flow, no annulus reversus, normal pericardium on CT/MRI).
  • Disproportionately elevated BNP/NT-proBNP for the degree of cavity dilation.
  • Extracardiac features suggesting amyloid (carpal tunnel syndrome, autonomic neuropathy, macroglossia, monoclonal gammopathy).
  • Sarcoid suspicion (bilateral hilar adenopathy, pulmonary infiltrates, atrioventricular block, ventricular tachycardia in a young patient).
  • Cardiac MRI with T1 mapping and extracellular volume fraction can substantially reduce the need for biopsy by identifying amyloid (markedly elevated ECV >0.40) and other infiltrative processes noninvasively.

When to refer to a tertiary cardiothoracic surgery program

Patients with confirmed or strongly suspected chronic constrictive pericarditis should be referred to a center with substantial pericardiectomy experience (>20 cases/year) for surgical evaluation. Indications for referral include: NYHA class III–IV symptoms despite optimal diuretic therapy, refractory ascites or hepatic congestion, cachexia, and confirmed equalization of pressures with ventricular interdependence. Earlier referral is preferred — pericardiectomy outcomes deteriorate sharply once cachexia, hepatic dysfunction, or renal failure develop. Complete pericardiectomy yields better long-term outcomes than partial ("waffle") procedures, especially in radiation-induced and TB-related cases.

S5 · Medical Therapy and Anti-inflammatory Trial

Medical therapy in constrictive pericarditis serves three purposes: relieving congestive symptoms in patients awaiting or unsuitable for surgery, treating the underlying inciting disease (notably tuberculosis), and, in hemodynamically stable patients, providing a 3–6 month anti-inflammatory trial to identify patients with transient or inflammatory constriction who may avoid pericardiectomy entirely. In advanced cases, medical therapy is supportive, controlling symptoms of congestion, and surgery should never be delayed (ESC 2025). Roughly 10–20% of patients diagnosed with subacute constriction will resolve with anti-inflammatory therapy alone, and an additional subset will improve enough to defer surgery.

Identifying candidates for an anti-inflammatory trial

The decision to attempt medical therapy before surgery applies to hemodynamically stable patients and hinges on evidence of active pericardial inflammation, that is, C-reactive protein elevation or pericardial enhancement on cardiac MRI (ESC 2025). Strong predictors of inflammatory and potentially reversible constriction include:

  • Recent (within 3 months) onset of constrictive symptoms following a documented episode of acute pericarditis.
  • Elevated CRP (>10 mg/L) or ESR (>30 mm/hr).
  • Pericardial late gadolinium enhancement on cardiac MRI (strong intensity).
  • Absent or minimal pericardial calcification on CT.
  • Pericardial thickness 4–8 mm without dense fibrocalcific stigmata.
  • Symptoms duration <6 months.

Patients with chronic fibrocalcific constriction (symptoms >6 months, dense calcification, no LGE, normal CRP) should proceed directly to surgical evaluation; medical trial in this subset is futile and risks deterioration.

Anti-inflammatory regimen

DrugDoseDurationNotes
Colchicine A0.5 mg PO BID (0.5 mg daily if <70 kg or CrCl <50)3 months minimumPrimary anti-inflammatory; reduces recurrence; check baseline CBC, BUN/Cr, LFTs; avoid with strong CYP3A4 inhibitors and P-gp inhibitors
Ibuprofen B600–800 mg PO TID with meals1–2 weeks at full dose, then taper over 4–6 weeksNSAID first-line for pain and inflammation; add PPI for gastroprotection; avoid in chronic kidney disease
Aspirin (alternative) B650–1000 mg PO TID for 1–2 weeks then taper4–6 weeks totalPreferred over ibuprofen if recent MI or coronary disease
Prednisone C0.25–0.5 mg/kg/day PO (max 50 mg) × 2–4 weeksSlow taper over 8–12 weeksReserved for NSAID failure, contraindication, or autoimmune etiology, and only after infection, particularly bacterial or tuberculous, has been excluded; higher recurrence rate; avoid abrupt withdrawal; calcium + vitamin D + bisphosphonate prophylaxis if >3 months
Anakinra (IL-1 antagonist) C100 mg SC daily3–6 monthsRefractory recurrent pericarditis; emerging evidence for steroid-dependent or colchicine-resistant constriction

Diuretic and supportive management

  • Loop diuretic — furosemide 40–80 mg PO daily or torsemide 20–40 mg PO daily; titrate to euvolemia. IV dosing for inpatient management of severe ascites or refractory edema.
  • Aldosterone antagonist — spironolactone 25–50 mg PO daily for ascites management; monitor potassium and creatinine.
  • Salt and fluid restriction — sodium <2 g/day; fluid <1.5 L/day in symptomatic congestion.
  • Rate control for atrial fibrillation — beta-blocker or calcium channel blocker; rhythm control rarely successful given chronic atrial dilation.
  • Anticoagulation — for atrial fibrillation per CHA₂DS₂-VASc; warfarin or DOAC.

Avoid aggressive volume reduction in undiagnosed constriction

Patients with constriction depend on elevated filling pressures to maintain cardiac output across the rigid pericardial constraint. Aggressive diuresis or dialysis can precipitate hypotension, syncope, and acute kidney injury. Diurese cautiously to relieve symptoms while preserving JVP at 8–12 cm H2O; avoid driving CVP to single digits before pericardiectomy is performed.

Tuberculous constrictive pericarditis

Patients with confirmed or strongly suspected TB pericarditis require directly observed therapy with the standard 4-drug regimen for 2 months of intensive therapy (rifampin + isoniazid + pyrazinamide + ethambutol) followed by 4–7 months of continuation phase (rifampin + isoniazid). Adjunctive prednisone 60 mg/day tapered over 6 weeks reduces the rate of progression to constriction in HIV-negative patients. Pericardiectomy is recommended in tuberculous pericarditis if the condition is not improving or is deteriorating after 4–8 weeks of antituberculosis therapy (ESC 2025).

Pearl/pitfall — medical therapy

Pearl · Cardiac MRI LGE identifies the responder phenotype

In hemodynamically stable patients with subacute constriction, a 3–6 month anti-inflammatory trial is warranted when there is evidence of active inflammation, that is, pericardial late gadolinium enhancement on cardiac MRI or C-reactive protein elevation; a raised CRP qualifies even without LGE (ESC 2025). Roughly 50–60% of LGE-positive patients show clinical and hemodynamic improvement on colchicine plus NSAID; patients with neither LGE nor CRP elevation have no evidence of active inflammation and should proceed directly to surgical referral without delay.

Pitfall · Treating chronic fibrocalcific constriction with NSAIDs and steroids

Patients with calcified pericardium, normal CRP, and symptoms longer than 6 months will not benefit from anti-inflammatory therapy. Initiating high-dose steroids in this setting risks fluid retention, infection, hyperglycemia, and a delay of months before surgical referral, by which time hepatic dysfunction and cachexia have developed and operative mortality has doubled. Reserve medical therapy for the inflammatory phenotype.

S6 · Pericardiectomy: Indications, Technique, and Outcomes

Radical pericardiectomy is the definitive therapy for chronic constrictive pericarditis and the only intervention that durably reverses the syndrome. Operative mortality at high-volume centers ranges from 5–10%, with 5-year survival of 60–80% in idiopathic, post-surgical, and TB-related cases. Outcomes are markedly worse for radiation-induced constriction (operative mortality 10–20%, 5-year survival 25–50%) due to coexisting myocardial fibrosis, restrictive disease, and prior thoracic radiation effects on coronary, valvular, and pulmonary structures.

Surgical indications

  • NYHA class III–IV symptoms despite optimal diuretic and medical therapy.
  • Persistent ascites or hepatic congestion refractory to medical management.
  • Confirmed chronic constrictive physiology (fibrocalcific pericardium, no LGE on MRI, symptoms >6 months, normal CRP).
  • Anti-inflammatory treatment not successful after 3–6 months in the inflammatory phenotype.
  • Progressive cachexia, hypoalbuminemia, or protein-losing enteropathy.

Contraindications and high-risk features

  • Severe right ventricular dysfunction with chronic atrophy (myocardial restriction superimposed on pericardial constriction).
  • Severe hepatic dysfunction with cirrhosis and ascites — may contraindicate pericardiectomy (ESC 2025). This is not the same as the venous congestion, hepatomegaly and ascites that constriction itself can cause (ESC 2015); refractory ascites or hepatic congestion is listed above as a surgical indication.
  • Severe renal dysfunction (eGFR <30 mL/min/1.73m²); doubles operative mortality.
  • Advanced age with multiple comorbidities; case-by-case risk-benefit.
  • Prior radiation therapy — relative contraindication; outcomes substantially worse but surgery still justified in selected cases.

Operative approach

ApproachDescriptionPros / Cons
Median sternotomy (preferred)Standard approach for radical pericardiectomy; cardiopulmonary bypass available if needed; allows access to all four chambers and great vesselsBest surgical exposure; cardiopulmonary bypass on standby; preferred for re-do or complex cases
Left anterolateral thoracotomyAlternative when sternotomy is contraindicated (prior CABG with patent grafts); limited posterior accessAvoids re-sternotomy; limited exposure; not standard
Complete (radical) pericardiectomyRemoval of pericardium from phrenic nerve to phrenic nerve, including both ventricles, atria, and great vessels back to AV grooveBest long-term outcomes; recommended approach; technically demanding
Partial ("waffle") pericardiectomyLimited resection of anterior pericardium with cross-hatch incisions on residual pericardiumHigher recurrence and worse outcomes; reserved for cases where complete resection is technically prohibitive

Perioperative considerations

  • Cardiopulmonary bypass — used selectively (intraoperative hemorrhage, suspected adherent epicardial structures, prior surgery); off-pump approach feasible in many idiopathic cases.
  • Low cardiac output syndrome — may occur in the first 24–48 hours after pericardiectomy due to abrupt restoration of right ventricular distensibility and ventricular dilation; supportive inotropes (dobutamine 2.5–5 mcg/kg/min IV or milrinone 0.25–0.5 mcg/kg/min IV) and judicious volume management.
  • Atrial arrhythmias — common postoperatively; rate control with beta-blocker; anticoagulation per CHA₂DS₂-VASc.
  • Hepatic and renal recovery — gradual over weeks to months; persistent dysfunction predicts worse long-term survival.

Outcomes by etiology

EtiologyOperative mortality5-year survivalKey determinant
Idiopathic / viral3–6%78–88%Best outcomes; complete pericardiectomy
Post-cardiac surgery5–10%65–75%Re-do thoracotomy challenges; cardiopulmonary bypass often required
Tuberculous5–10%70–80%Adequate antitubercular therapy critical
Autoimmune / CTD5–10%60–75%Coexisting myocardial involvement worsens outcomes
Post-radiation10–20%25–50%Coexisting myocardial fibrosis, restrictive cardiomyopathy, valvular and coronary disease
Cachectic / hepatic / renal failure15–30%30–50%Late referral; reversibility of organ dysfunction uncertain

Long-term follow-up

Patients should be followed at 1, 3, 6, and 12 months postoperatively, then annually thereafter. Symptomatic and hemodynamic improvement is gradual; complete resolution of ascites and edema may take 3–6 months. Persistent low cardiac output, ascites, or hepatic dysfunction at 6 months suggests incomplete resection, underlying restrictive cardiomyopathy, or radiation-induced myocardial disease and warrants reimaging with cardiac MRI and repeat hemodynamic assessment. Recurrent constriction is uncommon after complete pericardiectomy (<5%) but may occur after partial resection or in radiation-induced disease.

Pearl · Refer before cachexia develops

Operative mortality after pericardiectomy doubles or triples once cachexia, hepatic dysfunction, or renal failure are established. Patients with chronic fibrocalcific constriction and NYHA III symptoms should be referred for surgical evaluation immediately, even in the absence of refractory ascites — prophylactic referral preserves the window for low-mortality surgery.

Pitfall · Underestimating radiation-induced disease

Patients with post-radiation constriction often have superimposed restrictive cardiomyopathy, premature coronary disease, valvular disease, and pulmonary fibrosis. Pericardiectomy alone may not relieve symptoms, and operative mortality is 2–3× higher than idiopathic cases. Comprehensive preoperative assessment including coronary angiography, valve evaluation, pulmonary function testing, and cardiac MRI for myocardial fibrosis is essential.

Frequently Asked Questions

S7 · Practice Insights: Anti-inflammatory Trial Before Pericardiectomy Distinguishes Transient Constriction

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Constriction that follows a recent pericarditis can resolve with anti-inflammatory therapy alone, a possibility easily lost once surgery is on the table, and predictably this disease is mismanaged in one specific direction: pericardiectomy is rushed in patients who could have transient/reversible constriction responsive to 3-6 months of anti-inflammatory therapy. In experienced practice, the single most important question to ask before pericardiectomy referral in a hemodynamically stable patient is: "Is there active pericardial inflammation (raised CRP, or LGE or T2 edema on cardiac MRI), and has a structured anti-inflammatory trial been completed?"

Bedside Hemodynamic Distinguishers Experienced Clinicians Trust

The most reliable bedside finding distinguishing constriction from restriction is preserved medial tissue Doppler annulus velocity (annulus reversus: in constriction, lateral e' is usually lower than medial e') — restriction has uniformly low e' velocities at both annuli. Respirophasic septal shift on M-mode (interventricular septum bouncing toward LV during inspiration) is highly specific for constriction. Hepatic vein expiratory diastolic flow reversal >25% of forward flow is also very specific for constriction. In practice, these 3 echo findings together are diagnostic for constriction without requiring catheterization in most cases.

Cardiac MRI Identifies Reversible Constriction

Cardiac MRI with late gadolinium enhancement (LGE) of pericardium and T2-weighted edema imaging identifies active pericardial inflammation. Pericardial enhancement on LGE plus T2 edema strongly predicts response to anti-inflammatory therapy — these patients may have transient/reversible constriction that resolves with a 3-6 month course of anti-inflammatory therapy (NSAID + colchicine, ± steroids only after infection, particularly bacterial or tuberculous, has been excluded). In contrast, calcified pericardium (chronic, fibrotic) without active inflammation (no inflammatory enhancement and normal CRP) does not respond to anti-inflammatory therapy and requires pericardiectomy. Routinely, experienced practice requires cardiac MRI characterization before any pericardiectomy referral in patients without obvious calcified pericardium on CT.

Structured Anti-inflammatory Trial Protocol

For hemodynamically stable patients with active pericardial inflammation (raised CRP, or LGE or T2 edema on cardiac MRI), the anti-inflammatory trial lasts 3-6 months: ibuprofen 600-800 mg TID + colchicine 0.5 mg BID (lower in renal impairment), dosed as in the regimen table above, with the full NSAID dose kept until symptoms resolve and CRP normalizes before tapering. Add low-to-moderate-dose prednisone (0.2-0.5 mg/kg/day, tapered) only if NSAIDs are contraindicated or not tolerated, the response to NSAID plus colchicine is incomplete, or there is a specific indication such as systemic inflammatory disease, and only after infection, particularly bacterial or tuberculous, has been excluded. Echocardiographic re-assessment at 6, 8, and 12 weeks looking for resolution of septal bounce, normalization of hepatic vein flow, and improvement of symptoms. Approximately 50-70% of inflammatory constriction responds — these patients avoid pericardiectomy entirely. Anti-inflammatory treatment that is not successful after 3-6 months triggers surgical referral.

Pericardiectomy Timing and Center Volume

For non-responders to anti-inflammatory therapy or patients with calcified pericardium without active inflammation, pericardiectomy is the definitive treatment. The workflow: refer to high-volume centers (>25 pericardiectomies/year) — operative mortality drops from 10-15% at low-volume centers to 3-5% at high-volume centers, and long-term outcomes are substantially better. NYHA class III-IV at the time of surgery predicts worse outcomes; refer earlier rather than later if anti-inflammatory trial has failed. Total/radical pericardiectomy (including diaphragmatic pericardium) is preferred over partial procedures for durable relief.

Illustrative Scenario — Transient Constriction Resolved With 12 Weeks of NSAID + Colchicine

A man in his early fifties presented with progressive dyspnea, ascites, and bilateral pleural effusions 6 months after a viral pericarditis episode (treated initially with NSAIDs for 2 weeks). Echo showed septal bounce + annulus reversus + hepatic vein flow reversal — definite constriction. CT showed mildly thickened pericardium (4 mm) without calcification. The referring physician scheduled pericardiectomy. The treating clinicians requested cardiac MRI first: LGE of pericardium with associated T2 edema — active inflammation present. They argued for anti-inflammatory trial before surgical referral. Started ibuprofen 600 mg TID + colchicine 0.5 mg BID. At 6 weeks: ascites resolving, weight down 4 kg, septal bounce diminishing. At 12 weeks: complete clinical resolution, echo normalized (no septal bounce, normal hepatic vein flow), repeat cardiac MRI showed resolution of LGE/T2 edema. Pericardiectomy was canceled. He continued colchicine 0.5 mg daily for 6 additional months to prevent recurrence. At 3-year follow-up, no recurrent constriction.

Takeaway: cardiac MRI with LGE and T2 edema imaging identifies patients with active pericardial inflammation who may have transient/reversible constriction. A 3-6 month structured anti-inflammatory trial (NSAID + colchicine, ± steroids once infection, particularly bacterial or tuberculous, has been excluded) resolves 50-70% of inflammatory constriction without surgery. Pericardiectomy in hemodynamically stable MRI-positive inflammatory cases without trial commits to unnecessary surgery; pericardiectomy in calcified non-inflammatory cases is essential and should not be delayed.

the established Protocol Adjustments to Standard Constrictive Pericarditis Management

  1. Echo triad for diagnosis without catheterization: Septal bounce + annulus reversus (preserved/elevated medial e' at or above lateral e' = constriction; uniformly low = restriction) + hepatic vein expiratory diastolic flow reversal >25%. Cath only for equivocal cases.
  2. Cardiac MRI mandatory before pericardiectomy referral: LGE + T2 edema identify transient/reversible inflammatory constriction. Without active inflammation in non-calcified cases, proceed to surgery.
  3. 3-6 month anti-inflammatory trial for hemodynamically stable inflammatory constriction: Ibuprofen 600-800 TID at full dose for an initial 1-2 weeks and until symptoms resolve and CRP normalizes, then tapered, + colchicine 0.5 BID; add prednisone 0.2-0.5 mg/kg/day (tapered) only if NSAIDs are contraindicated or not tolerated, the response is incomplete, or there is a specific indication such as systemic inflammatory disease, and only after infection, particularly bacterial or tuberculous, has been excluded. 50-70% respond and avoid pericardiectomy entirely. Continue colchicine 6 additional months after resolution to prevent recurrence.
  4. High-volume center pericardiectomy referral: >25 cases/year. Operative mortality 3-5% vs 10-15% low-volume. NYHA III-IV worse outcome — refer earlier after failed anti-inflammatory trial. Total pericardiectomy preferred over partial.
1. What is the most reliable bedside finding for constrictive pericarditis?
Markedly elevated jugular venous pressure with prominent y descent and Kussmaul sign (paradoxical rise in JVP during inspiration) is the most reliable bedside finding. JVP is elevated to the angle of the jaw in nearly all symptomatic patients, and the y descent is exaggerated due to rapid early diastolic filling before pericardial constraint engages. Kussmaul sign has 90% specificity though only 50–60% sensitivity. The pericardial knock — a high-frequency early diastolic sound 60–120 ms after S2 at the lower left sternal border — is highly specific (95%) when present but heard in only 30–60% of cases. A disproportionately low BNP relative to the degree of congestion is a key supportive clue.
2. How do I distinguish constriction from restrictive cardiomyopathy?
The two share a clinical phenotype but diverge on multiple tests: BNP/NT-proBNP is markedly elevated in restriction but disproportionately low in constriction; pericardium is >4 mm and often calcified in constriction but normal in restriction; tissue Doppler shows annulus reversus (medial e′ ≥ lateral e′, with preserved medial e′) in constriction but reduced e′ (<7 cm/s) in restriction; mitral E respiratory variation is ≥25% in constriction and <10% in restriction; pulmonary artery systolic pressure is usually <55 mm Hg in constriction and often >55 in restriction. Hatle's ventricular interdependence index >1.1 on simultaneous LV/RV catheterization has 97% sensitivity and 100% specificity for constriction. Endomyocardial biopsy and cardiac MRI with T1 mapping diagnose specific restrictive cardiomyopathies (amyloid, sarcoid, hemochromatosis).
3. When should I trial anti-inflammatory therapy versus refer for surgery?
Trial 3–6 months of anti-inflammatory therapy (ibuprofen 600–800 mg TID at full dose for an initial 1–2 weeks and until symptoms resolve and CRP normalizes, then tapered, + colchicine 0.5 mg BID, ± prednisone 0.25–0.5 mg/kg/day) in hemodynamically stable patients with a transient or new diagnosis of constriction and evidence of pericardial inflammation, that is, C-reactive protein elevation or pericardial enhancement on cardiac MRI (ESC 2025). Add prednisone only if NSAIDs are contraindicated or not tolerated, the response to NSAID plus colchicine is incomplete, or there is a specific indication (ESC 2025), and only after infection, particularly bacterial or tuberculous, has been excluded (ESC 2015). Roughly 10–20% of inflammatory cases resolve on anti-inflammatory therapy alone. Refer directly for pericardiectomy when there is no active inflammation (normal CRP and no pericardial enhancement on MRI) or when anti-inflammatory treatment is not successful after 3–6 months. In advanced cases, medical therapy is supportive, controlling symptoms of congestion, and surgery should never be delayed. Delaying surgery in chronic fibrocalcific constriction increases operative mortality once cachexia or hepatic dysfunction develop.
4. What pericardial thickness on CT or MRI confirms constriction?
Pericardial thickness greater than 4 mm on ECG-gated cardiac CT or MRI is the structural threshold supporting constriction (normal pericardium ≤2 mm). However, 18–20% of surgically confirmed cases — particularly post-cardiac surgery and radiation-induced — have a pericardium ≤2 mm thick, sometimes referred to as "constriction without thickening." Diagnosis must therefore integrate pericardial morphology with hemodynamic findings on echocardiography or invasive catheterization. Pericardial calcification is present in 25–35% overall and up to 50% of TB-related cases; CT detects calcium far better than MRI. Late gadolinium enhancement on cardiac MRI identifies inflammation and predicts response to anti-inflammatory therapy.
5. What is the operative mortality and 5-year survival of pericardiectomy?
In experienced centers, overall operative mortality for pericardiectomy is 5–10% and 5-year survival is 60–80%. Outcomes vary by etiology: idiopathic and viral cases have the lowest mortality (3–6%) and best 5-year survival (78–88%); post-cardiac surgery cases face higher mortality (5–10%) due to re-do thoracotomy challenges; tuberculous cases run 5–10% mortality with 70–80% survival when adequate antitubercular therapy precedes surgery; post-radiation cases have the worst outcomes (10–20% mortality, 25–50% 5-year survival) due to coexisting myocardial fibrosis, restrictive cardiomyopathy, valvular and coronary disease. Late referral with cachexia, hepatic dysfunction, or renal failure doubles or triples operative mortality. Complete (radical) pericardiectomy yields better outcomes than partial waffle resection.
6. Why does BNP stay low in constrictive pericarditis despite severe congestion?
Brain natriuretic peptide is released by ventricular cardiomyocytes in response to myocardial stretch. In constrictive pericarditis, the rigid pericardium prevents the ventricular wall from stretching despite markedly elevated chamber pressures, so the natriuretic peptide release signal is blunted. BNP is typically <200 pg/mL and NT-proBNP <1,000 pg/mL even in patients with JVP to the jaw, ascites, hepatomegaly, and severe peripheral edema. This disproportionately low BNP is a high-yield diagnostic clue and should prompt evaluation for pericardial constraint when the clinical picture suggests right heart failure but BNP is unexpectedly modest. In restrictive cardiomyopathy, by contrast, the diseased myocardium itself is stretched and BNP/NT-proBNP rises substantially (often >500/>5,000).
7. What postoperative complications and recovery should I expect after pericardiectomy?
The major early complication is low cardiac output syndrome in the first 24–48 hours, occurring in 15–30% of patients due to abrupt restoration of right ventricular distensibility and ventricular dilation; managed with inotropes (dobutamine 2.5–5 mcg/kg/min or milrinone 0.25–0.5 mcg/kg/min) and judicious volume. Atrial arrhythmias, particularly atrial fibrillation, occur in 30–40% and are managed with beta-blocker rate control and anticoagulation per CHA₂DS₂-VASc. Bleeding requiring re-exploration occurs in 5–10%. Symptomatic recovery is gradual: dyspnea improves over weeks, ascites and edema resolve over 3–6 months, and hepatic and renal function recover slowly if not irreversibly damaged. Persistent symptoms at 6 months suggests incomplete resection, underlying restrictive cardiomyopathy, or radiation-induced myocardial disease and warrants repeat imaging and hemodynamic assessment. Recurrent constriction after complete pericardiectomy is uncommon (<5%).

Leave a Reply

Your email address will not be published. Required fields are marked *